Glenmark Launches RYALTRIS in Brazil, Expands Global Respiratory Reach

RYALTRIS is now approved in 57 markets worldwide, with Brazil becoming the latest commercial launch market.
Allergic rhinitis affects an estimated 20%-30% of Brazil’s population, or roughly 40-60 million people.

Reader Takeaway: Brazil expands RYALTRIS reach, but investor value depends on sustained commercial penetration across global markets.

What just happened

Glenmark Pharmaceuticals has launched RYALTRIS nasal spray in Brazil through its wholly owned subsidiary, Glenmark Specialty S.A.

The medicine is indicated for moderate to severe symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older. The launch follows approval from Brazil’s health regulator, ANVISA.

RYALTRIS combines olopatadine hydrochloride, an antihistamine, with mometasone furoate, a corticosteroid, in a single intranasal spray.

Why this matters

Brazil is the largest healthcare market in Latin America, making the launch strategically relevant for Glenmark’s respiratory portfolio.

The company estimates allergic rhinitis affects about 20%-30% of Brazil’s population, corresponding to roughly 40-60 million people. That gives Glenmark access to a large treatment market as it expands its branded innovative product business.

RYALTRIS is Glenmark’s first globally commercialised branded innovative product. Its reach now spans 57 approved markets, including the United States, European Union, United Kingdom, Australia, South Korea, Russia and China.

What changes now

The Brazil launch extends Glenmark’s strategy of building higher-value branded products rather than relying only on traditional generics.

For investors, the key point is not merely regulatory approval but actual prescription growth and market penetration after launch. Successful commercialisation in a major Latin American market could strengthen the contribution of respiratory products to Glenmark’s broader product mix.

The launch also gives the company another market in which it can test the scalability of a product already approved across several major geographies.

Risks to watch

The filing does not disclose expected Brazil revenue, pricing, market share targets or near-term financial contribution from RYALTRIS.

That means the commercial impact cannot yet be quantified. Competition, physician adoption and patient uptake will determine how meaningful the launch becomes for Glenmark’s earnings profile.

What to track next

Investors should monitor RYALTRIS sales growth in Brazil, additional international launches, market penetration across existing geographies and the contribution of branded innovative products to Glenmark’s overall revenue mix.